IFNB1 and relapsing-remitting multiple sclerosis: Recombinant IFN-β administered to patients with RRMS is associated with increased proliferation of CD56 bright natural killer (NK) cells, Foxp3+ regulatory T cells (Treg), as well as FoxA1+ Treg cells, favoring Th2 over Th1 responses (60, 61, 72) (Figure 2).